Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with the heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during the shortage of vaccine supply are available. Forty-four cancer patients who previously received the heterologous Coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Luangdilok, Sutima, Wanchaijiraboon, Passakorn, Pakvisal, Nussara, Susiriwatananont, Thiti, Zungsontiporn, Nicha, Sriuranpong, Virote, Sainamthip, Panot, Suntronwong, Nungruthai, Vichaiwattana, Preeyaporn, Wanlapakorn, Nasamon, Poovorawan, Yong, Teeyapun, Nattaya, Tanasanvimon, Suebpong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608216/
https://www.ncbi.nlm.nih.gov/pubmed/36298478
http://dx.doi.org/10.3390/vaccines10101613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608216/
https://www.ncbi.nlm.nih.gov/pubmed/36298478
http://dx.doi.org/10.3390/vaccines10101613

Ejemplares similares